早产儿肺透明膜病(hyaline membrane disease,HMD)是早产儿常见并发症,一旦发生,病情重,治疗困难,病死率高,存活者多遗留后遗症。早期干预用药促进早产儿肺成熟,提高机体防御能力是降低新生儿死亡率的关键。我院自2006年3月～2007年3月应用沐舒坦(勃林格殷格翰公司生产)防治早产儿肺透明膜病,取得了较好的疗效,现报道如下。 Hyaline membrane disease (HMD) in preterm infants is a common complication in preterm infants. Once the disease occurs, the disease is serious, the treatment is difficult and the mortality rate is high. Survivors have many residual sequelae. Early intervention medication to promote lung maturation of premature children and improve the body’s defensive ability is to reduce neonatal mortality key. Our hospital since March 2006 ~ March 2007 application of Mucosolvan (Boehringer Ingelheim company) prevention and treatment of premature children with hyaline membrane disease, and achieved good results, are reported below.